Promomed Group wins two awards of IP RUSSIA AWARDS 2023
Promomed Group, one of the leaders in the Russian pharmaceutical industry, was awarded the IP RUSSIA AWARDS (IPRA) 2023. The award ceremony took place last week in Moscow.
Silver award in the nomination “The best strategy for the management and protection of the intellectual property in chemistry and pharmaceuticals industry” went to the Promomed Group employees Maria Porokhnya, Director of Intellectual Property, Ksenia Malysheva, Head of the Patent Department, and Ulyana Aladysheva, Intellectual Property specialist. Evgenia Levina, Head of the Trademark Department of Promomed Group, received a well-deserved award among the top three winners in the nomination “For her contribution to the fight against counterfeiting”.
“Pharmaceuticals all over the world is one of the industries where the role of intellectual property is especially great, and obtaining patents is especially difficult due to the specifics and complexity of our subjects for patenting. We are glad that in a short period of time we managed to demonstrate results, replenish the intellectual property portfolio of the company and implement a strategy to create effective protection of targeted antiviral therapy products. These activities are ongoing, the development and patenting of new in-demand drugs is carried out with tripled force and speed. We thank the organizers of the award and the distinguished jury for their high appreciation of the achievements of our team, and we will surprise you with new implemented projects next year!” said Maria Porokhnya.
IP RUSSIA AWARDS became the first Russian contest in the field of intellectual property. The event is supported by the Federal Service for Intellectual Property (Rospatent) and the Federal Institute of Industrial Property (FIPS), and is designed to identify the best organizations and specialists in this field.
Promomed Group, being one of the largest Russian manufacturers of pharmaceuticals, is actively engaged in the development and launch of innovative drugs on the market, both replacing medicines that have become unavailable, and completely new ones, which are unique developments of the Group. Experts of the Promomed Group believe that patent protection of products and the accruement of corporate intangible assets is a necessary element for the development of the Group’s own innovations and the pharmaceutical industry as a whole.
